A Phase 1 interventional study of Palbociclib 75 mg Capsule in Healthy, Hepatic Insufficiency, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-24.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.
Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 24th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2015, is one of 42 in phase 1, and was the 23rd registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Incyte Corporation · Sites in United States
Ages 18–80
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is close to the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 28 across the 48 interventional studies, 28 across the 3 observational. Of the 47 that completed or were terminated, 16 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 52 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 6 studies filed under Hepatic Insufficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatic Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
| NCT07559474Incyte CorporationA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | 2027-04-13 |
| NCT07677358PfizerA Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease | 2027-08-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Hepatic Insufficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 1 study to describe the plasma pharmacokinetics of a single oral 75mg dose of palbociclib administered to healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function.
This is a 4-cohort single period study. The four cohorts will consist of healthy volunteers, and subjects with mild, moderate, and severely impaired hepatic function. Each cohort will receive the same treatment consisting of a single oral 75mg dose of palbociclib administered with food. Serial PK samples will be drawn up to 120 hours post dose for the cohort consisting of healthy volunteers, and will continue until up to 192 hours post-dose for the cohorts of hepatic impairment subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort of Healthy Volunteers
Drug: Palbociclib 75 mg Capsule
Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
Drug: Palbociclib 75 mg Capsule
Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
Drug: Palbociclib 75 mg Capsule
Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
Drug: Palbociclib 75 mg Capsule
Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
Also known as: Palbociclib, PD-0332991
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf)
AUCinf is area under the plasma concentration time curve from time 0 extrapolated infinite time. It is calculated as AUClast + (Clast/kel), where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration, Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Maximum Plasma Concentration (Cmax)
Cmax is maximum plasma concentration. It is observed directly from data.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Unbound AUCinf (AUCinf,u)
AUCinf,u is unbound AUCinf, where AUCinf is area under the concentration-time curve from time 0 extrapolated to infinite time. It is obtained by fu\*AUCinf, where fu is the fraction of unbound drug in plasma.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
AUClast is area under the plasma concentration time curve from time 0 to time of last quantifiable concentration. It is obtained from linear/log trapezoidal method.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Unbound AUClast (AUClast,u)
AUClast,u is unbound AUClast, where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. It is obtained by fu\*AUClast, where fu is the fraction of unbound drug in plasma.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Apparent Clearance After Oral Dose(CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance is obtained by dose/AUCinf, where AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Unbound CL/F (CLu/F)
CLu/F is unbound CL/F, where CL/F is apparent clearance after oral dose. It is obtained by dose/AUCinf,u, where AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Unbound Cmax (Cmax,u)
Cmax,u is unbound Cmax, where Cmax is maximum plasma concentration. It is obtained by fu\*Cmax, where fu is fraction of unbound drug in plasma.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Fraction of Unbound Drug in Plasma (fu)
Fu is the fraction of unbound drug in plasma. It is obtained from measurement of protein binding.
Time frame: Eight (8) hours post-dose.
Terminal Half-Life (t1/2)
T1/2 is terminal half-life. It is obtained by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Time for Cmax (Tmax)
Tmax is time for maximum plasma concentration. It is observed directly from data as time of first occurrence of maximum plasma concentration.
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Apparent Volunm of Distribution After Oral Dose (Vz/F)
Vz/F is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. It is influenced by the fraction absorbed. It is obtained by dose/(AUCinf•kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.
Time frame: pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Unbound Vz/F (Vz,u/F)
Vz,u/F is unbound Vz/F, where Vz/F is apparent volume of distribution after oral dose. It is obtained by dose/(AUCinf,u\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).
Time frame: Pre-dose and 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose for for all participants. Additional pharmacokinetics samples were collected from participants in hepatic impairment cohorts (Cohorts 2, 3 and 4) at 144, 168, and 192 hours post-dose.
Number of Participants With Treatment Emergent Adverse Events
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Time frame: Adverse events were recorded on the Case Report Form from the time the participant had taken at least 1 dose of palbociclib through the participant's last visit.
Number of Participants With Treatment Emergent Serious Adverse Events
A serious adverse event is any untoward medical occurrence at any dose that resulted in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; or results in congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No).
Time frame: The active reporting period for serious adverse events began from the time that the participant provided informed consent through and including 28 calendar days after the last administration of palbociclib.
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.
Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, inclusive of baseline values.
Number of Participants With Physical Examination Test Abnormalities (Change From Prior Visit)
A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.
Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4.
Number of Participants With Post Baseline Vital Signs Values Meeting Categorical Summarization Criteria
The number of participants with post baseline vital signs values meeting the following criteria was reported: A. absolute value of supine systolic blood pressure less than (\<) 90 mmHg; B. absolute value of diastolic blood pressure \<50 mmHg; C. absolute value of supine pulse rate \<40 bmp; D. absolute value of supine pulse rate larger than (\>) 120 bmp; E. maximum increase from baseline in supine systolic blood pressure larger than and equal to (\>=) 30 mmHg; F. maximum increase from baseline in supine diastolic blood pressure \>=20 mmHg; G. maximum decrease from baseline in supine systolic blood pressure \>=30 mmHg; and H. maximum decrease from baseline in supine diastolic blood pressure \>=20 mmHg.
Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.
Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Absolute Values)
Maximum absolute values of post baseline electrocardiogram were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum absolute values of post baseline electrocardiogram meeting the following criteria was reported: (1) PR interval \>=300 msec; (2) QRS complex \>=140 msec; (3) QT interval 450 to \<480 msec; (4) QT interval 480 to \<500 msec; (5) QT interval \>= 500 msec; (6) QTcB 450 to \<480 msec; (7) QTcB 480 to \<500 msec; (8) QTcB \>= 500 msec; (9) QTcF 450 to \<480 msec; (10) QTcF 480 to \<500 msec; and (11) QTcF \>=500 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.
Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.
Number of Participants With Post Baseline Electrocardiogram Values Meeting Categorical Summarization Criteria (Maximum Increase From Baseline)
Maximum increases from baseline for post baseline electrocardiogram values were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum increase from baseline for post baseline electrocardiogram values meeting the following criteria was reported: (1) percent change of PR interval \>=25/50%; (2) percent change of QRS complex \>=50%; (3) QT interval 30 to \<60 msec; (4) QT interval \>= 60 msec; (5) QTcB 30 to \<60 msec; (6) QTcB \>= 60 msec; (7) QTcF 30 to \<60 msec; and (8) QTcF \>= 60 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.
Time frame: Baseline up to Day 6 for Cohort 1 and to Day 9 for Cohorts 2, 3, and 4, not including baseline values.
Number of Participants With Concomitant Medications
Treatments taken after the first dose of study treatment were documented as concomitant treatments.
Time frame: From screening through and including Day 6 for Cohort 1, and from screening through and including Day 9 for Cohorts 2, 3, and 4.
| Milestone | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 |
| Received treatment | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
AUCinf is area under the plasma concentration time curve from time 0 extrapolated infinite time. It is calculated as AUClast + (Clast/kel), where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration, Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| nanogram*hour/milliliter (ng*hr/mL) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) | 1031 ± 24 | 758.9 ± 31 | 1189 ± 22 | 1378 ± 29 |
Cmax is maximum plasma concentration. It is observed directly from data.
| nanogram/milliliter (ng/mL) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) | 28.64 ± 20 | 27.20 ± 37 | 33.72 ± 28 | 37.20 ± 48 |
AUCinf,u is unbound AUCinf, where AUCinf is area under the concentration-time curve from time 0 extrapolated to infinite time. It is obtained by fu\*AUCinf, where fu is the fraction of unbound drug in plasma.
| ng*hr/mL | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Unbound AUCinf (AUCinf,u) | 196.6 ± 26 | 163.2 ± 32 | 264.1 ± 25 | 347.8 ± 23 |
AUClast is area under the plasma concentration time curve from time 0 to time of last quantifiable concentration. It is obtained from linear/log trapezoidal method.
| ng*hr/mL | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) | 973.3 ± 24 | 708.6 ± 34 | 1125 ± 24 | 1311 ± 31 |
AUClast,u is unbound AUClast, where AUClast is area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. It is obtained by fu\*AUClast, where fu is the fraction of unbound drug in plasma.
| ng*hr/mL | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Unbound AUClast (AUClast,u) | 185.5 ± 26 | 152.4 ± 35 | 250.3 ± 26 | 331.0 ± 24 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance is obtained by dose/AUCinf, where AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.
| liter/hour (L/hr) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Apparent Clearance After Oral Dose(CL/F) | 72.64 ± 24 | 98.84 ± 31 | 63.15 ± 22 | 54.42 ± 29 |
CLu/F is unbound CL/F, where CL/F is apparent clearance after oral dose. It is obtained by dose/AUCinf,u, where AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).
| L/hr | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Unbound CL/F (CLu/F) | 381.3 ± 26 | 459.2 ± 32 | 283.8 ± 25 | 215.8 ± 23 |
Cmax,u is unbound Cmax, where Cmax is maximum plasma concentration. It is obtained by fu\*Cmax, where fu is fraction of unbound drug in plasma.
| ng/mL | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Unbound Cmax (Cmax,u) | 5.456 ± 23 | 5.858 ± 37 | 7.501 ± 34 | 9.399 ± 47 |
Fu is the fraction of unbound drug in plasma. It is obtained from measurement of protein binding.
| ratio | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Fraction of Unbound Drug in Plasma (fu) | 0.1910 ± 0.015 | 0.2157 ± 0.014 | 0.2236 ± 0.025 | 0.2546 ± 0.036 |
T1/2 is terminal half-life. It is obtained by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| hour (hr) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Terminal Half-Life (t1/2) | 25.84 ± 4.22 | 27.23 ± 5.49 | 35.03 ± 4.61 | 33.84 ± 5.39 |
Tmax is time for maximum plasma concentration. It is observed directly from data as time of first occurrence of maximum plasma concentration.
| hr | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Time for Cmax (Tmax) | 8.00 (6.00 to 12.0) | 6.00 (6.00 to 6.00) | 6.00 (2.00 to 6.00) | 6.00 (2.00 to 8.00) |
Vz/F is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. It is influenced by the fraction absorbed. It is obtained by dose/(AUCinf•kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf is the area under the concentration-time curve from time 0 extrapolated to infinite time.
| liter (L) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Apparent Volunm of Distribution After Oral Dose (Vz/F) | 2679 ± 18 | 3814 ± 36 | 3168 ± 26 | 2627 ± 29 |
Vz,u/F is unbound Vz/F, where Vz/F is apparent volume of distribution after oral dose. It is obtained by dose/(AUCinf,u\*kel), where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, and AUCinf,u is unbound AUCinf (area under the concentration-time curve from time 0 extrapolated to infinite time).
| L | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Unbound Vz/F (Vz,u/F) | 14060 ± 24 | 17730 ± 36 | 14260 ± 32 | 10410 ± 30 |
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
| participant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 2 | 0 | 2 | 1 |
A serious adverse event is any untoward medical occurrence at any dose that resulted in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; or results in congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity are counted as treatment emergent. Relatedness to palbociclib is assessed by the investigator (Yes/No).
| participant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events | 0 | 0 | 1 | 0 |
Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.
| participants | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) | 6 | 6 | 5 | 7 |
A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The limited or abbreviated physical examination was focused on general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.
| participant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Number of Participants With Physical Examination Test Abnormalities (Change From Prior Visit) | 0 | 0 | 2 | 0 |
The number of participants with post baseline vital signs values meeting the following criteria was reported: A. absolute value of supine systolic blood pressure less than (\<) 90 mmHg; B. absolute value of diastolic blood pressure \<50 mmHg; C. absolute value of supine pulse rate \<40 bmp; D. absolute value of supine pulse rate larger than (\>) 120 bmp; E. maximum increase from baseline in supine systolic blood pressure larger than and equal to (\>=) 30 mmHg; F. maximum increase from baseline in supine diastolic blood pressure \>=20 mmHg; G. maximum decrease from baseline in supine systolic blood pressure \>=30 mmHg; and H. maximum decrease from baseline in supine diastolic blood pressure \>=20 mmHg.
| participant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| criterion A | 0 | 1 | 0 | 0 |
| criterion B | 0 | 0 | 0 | 2 |
| criterion C | 0 | 0 | 0 | 0 |
| criterion D | 0 | 0 | 0 | 0 |
| criterion E | 0 | 0 | 0 | 0 |
| criterion F | 0 | 0 | 0 | 0 |
| criterion G | 0 | 0 | 1 | 1 |
| criterion H | 0 | 0 | 0 | 1 |
Maximum absolute values of post baseline electrocardiogram were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum absolute values of post baseline electrocardiogram meeting the following criteria was reported: (1) PR interval \>=300 msec; (2) QRS complex \>=140 msec; (3) QT interval 450 to \<480 msec; (4) QT interval 480 to \<500 msec; (5) QT interval \>= 500 msec; (6) QTcB 450 to \<480 msec; (7) QTcB 480 to \<500 msec; (8) QTcB \>= 500 msec; (9) QTcF 450 to \<480 msec; (10) QTcF 480 to \<500 msec; and (11) QTcF \>=500 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.
| participant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| PR interval >=300 msec | 0 | 0 | 0 | 0 |
| QRS complex >=140 msec | 0 | 0 | 0 | 0 |
| QT interval 450 to <480 msec | 0 | 1 | 1 | 4 |
| QT interval 480 to <500 msec | 0 | 2 | 0 | 0 |
| QT interval >= 500 msec | 0 | 0 | 0 | 0 |
| QTcB 450 to <480 msec | 0 | 1 | 2 | 2 |
| QTcB 480 to <500 msec | 0 | 0 | 0 | 3 |
| QTcB >= 500 msec | 0 | 0 | 0 | 0 |
| QTcF 450 to <480 msec | 0 | 1 | 0 | 5 |
| QTcF 480 to <500 msec | 0 | 0 | 0 | 0 |
| QTcF >=500 msec | 0 | 0 | 0 | 0 |
Maximum increases from baseline for post baseline electrocardiogram values were summarized for PR interval, QRS complex, QT interval, QTcB (QT interval calculated using Bazett's correction factor), and QTcF (QT interval calculated using Fridericia's correction factor). The number of participants with maximum increase from baseline for post baseline electrocardiogram values meeting the following criteria was reported: (1) percent change of PR interval \>=25/50%; (2) percent change of QRS complex \>=50%; (3) QT interval 30 to \<60 msec; (4) QT interval \>= 60 msec; (5) QTcB 30 to \<60 msec; (6) QTcB \>= 60 msec; (7) QTcF 30 to \<60 msec; and (8) QTcF \>= 60 msec. Seven (7) participants in each cohort were evaluated for electrocardiogram tests except that 6 participants in the moderate hepatic impairment cohort (Cohort 3) were evaluated for PR interval.
| paticipant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| percent change of PR interval >=25/50% | 0 | 0 | 0 | 0 |
| percent change of QRS complex >=50% | 0 | 0 | 0 | 0 |
| QT interval 30 to <60 msec | 0 | 0 | 0 | 2 |
| QT interval >= 60 msec | 0 | 0 | 0 | 0 |
| QTcB 30 to <60 msec | 0 | 0 | 0 | 1 |
| QTcB >= 60 msec | 0 | 0 | 0 | 1 |
| QTcF 30 to <60 msec | 0 | 0 | 0 | 0 |
| QTcF >= 60 msec | 0 | 0 | 0 | 1 |
Treatments taken after the first dose of study treatment were documented as concomitant treatments.
| participant | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| Number of Participants With Concomitant Medications | 0 | 3 | 7 | 7 |
Collected over For adverse event, from the time participant took at least 1 dose of palbociclib through the last visit. For serious adverse event, from the participant provided informed consent through 28 calendar days post last administration of palbociclib.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | — | 0/7 (0%) | 2/7 (28.6%) |
| Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | — | 0/7 (0%) | 0/7 (0%) |
| Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | — | 1/7 (14.3%) | 2/7 (28.6%) |
| Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) | — | 0/7 (0%) | 1/7 (14.3%) |
| Event | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/7 | 0/7 | 1/7 | 0/7 |
| Event | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/7 | 0/7 | 0/7 | 0/7 |
| VomitingGastrointestinal disorders | 1/7 | 0/7 | 0/7 | 0/7 |
| Infusion site bruisingGeneral disorders | 0/7 | 0/7 | 1/7 | 0/7 |
| Infusion site reactionGeneral disorders | 1/7 | 0/7 | 0/7 | 0/7 |
| HeadacheNervous system disorders | 0/7 | 0/7 | 1/7 | 1/7 |
| Radial nerve compressionNervous system disorders | 0/7 | 0/7 | 1/7 | 0/7 |
| DiarrheaGastrointestinal disorders | 0/7 | 0/7 | 1/7 | 0/7 |
| Age, Continuous(years) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) | Total |
|---|---|---|---|---|---|
| Mean | 57.6 ± 2.6 | 53.9 ± 5.1 | 57.9 ± 4.2 | 57 ± 5.3 | 56.6 ± 4.5 |
| Sex: Female, Male(Participants) | Palbociclib 75 mg (Normal Hepatic Function, Cohort 1) | Palbociclib 75 mg (Mild Hepatic Impairment, Cohort 2) | Palbociclib 75 mg (Moderate Hepatic Impairment, Cohort 3) | Palbociclib 75 mg (Severe Hepatic Impairment, Cohort 4) | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 2 | 4 | 10 |
| Male | 4 | 6 | 5 | 3 | 18 |
Ran from Mar 2015 to primary completion in Oct 2016, 18 months.
Results were first posted in Jan 2018, 1 year 3 months after primary completion.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 18 months is above that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib